Leritrelvir
Based on 1 Customer Validation
Leritrelvir (RAY1216) is an orally active SARS-CoV-2 main protease slow-tight inhibitor with a Ki of 8.6 nM.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 97.92%
- CAS No.: 2923310-64-7
- Formule: C31H44F3N5O6
- Masse moléculaire:639.71
-
Stockage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Ki: 8.6 nM (SARS-CoV-2 main protease)[1]
Leritrelvir (RAY1216) has a drug-target residence time of 104 min[1].
Leritrelvir is covalently attached to the catalytic Cys145 through the α-ketoamide warhead[1].
Leritrelvir (0-1000 nM; 72 h) shows antiviral activities against SARS-CoV-2 wild type ancestral strain and variants[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Vero E6 cells inoculated with SARS-CoV-2 WT, Alpha, Beta, Delta, Omicron BA.1 and Omicron 247 BA.5 strains
-
Concentration:0-1000 nM
-
Incubation Time:72 h
-
Result:The half-maximal effective concentration (EC50) values against different SARS-CoV-2 variants were 95 nM (WT), 130 nM (Alpha), 277 nM (Beta), 97 nM (Delta), 86 nM (Omicron BA.1) and 158 nM (Omicron BA.5), respectively.
Compound pharmacokinetics parameters in different animal species[1]
| Compound | Species | dose (mg/kg) | Cmax (nM) | Tmax (h) | AUC(0-last) (nM h) | Cl (mL/min/kg) | Vdss (L/kg) | T1/2 (h) | oral F (%) |
| Mouse | 3.0 (IV) | - | - | 7789 | 10 | 1.4 | 3.8 | - | |
| 10 (PO) | 1287 | 2.0 | 5698 | - | - | 2.6 | 22 | ||
| RAY1216 | rat | 2.0 (IV) | - | - | 4505 | 12.5 | 1.1 | 2.2 | - |
| 10 (PO) | 916 | 0.9 | 7429 | - | - | 4.3 | 33 | ||
| cynomolgus macaque | 1.0 (IV) | - | - | 1157 | 22.5 | 1.0 | 0.9 | - | |
| 5.0 (PO) | 102 | 1.5 | 458 | - | - | 14.9 | 8 |
Cmax: the maximum observed concentration of the drug collected in bodily material from subjects in a clinical study
Tmax: the time it takes to reach the maximum concentration or time to Cmax
AUC: "Area Under the Curve” and represents the total exposure of the drug experienced by the subject in a clinical study
Cl: total plasma clearance
Vdss: Steady state volume of distribution
T1/2: Half-time is the time it takes for half the drug concentration to be eliminated
oral (F%): Oral bioavailability
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female human ACE2 transgenic C57BL/6 mouse, SARS-CoV-2 infection model[1]
-
Dosage:150, 300 and 600 mg/kg/day
-
Administration:Intragastric administration, 5 days
-
Result:Protected mice infected with SARS-CoV-2 by 100%, 43% and 14% at 600, 300 and 150 mg/kg, respectively. Decreased viral titres in lungs significantly compared with the infection-only group. Reduced virus induced pathology.
-
Animal Model:Male CD-1 mouse, male SD rat and male cynomolgus macaque[1]
-
Dosage:1-10 mg/kg
-
Administration:PO or IV (Pharmacokinetic Analysis)
-
Result:Showed promising human pharmacokinetics profile.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2923310-64-7
-
Appearance Solid
-
Masse moléculaire 639.71
-
Formule C31H44F3N5O6
-
Color White to off-white
-
SMILES
O=C(C(F)(F)F)N[C@H](C(N1C[C@H](CCC2)[C@H]2[C@H]1C(N[C@@H](C[C@]3([H])CCNC3=O)C(C(NC4CCCC4)=O)=O)=O)=O)C5CCCCC5
-
Synonyms
RAY1216
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvant et solubilité
DMSO : 83.33 mg/mL (130.26 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (286 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.5632 mL | 7.8160 mL | 15.6321 mL | 39.0802 mL |
| 5 mM | 0.3126 mL | 1.5632 mL | 3.1264 mL | 7.8160 mL | |
| 10 mM | 0.1563 mL | 0.7816 mL | 1.5632 mL | 3.9080 mL | |
| 15 mM | 0.1042 mL | 0.5211 mL | 1.0421 mL | 2.6053 mL | |
| 20 mM | 0.0782 mL | 0.3908 mL | 0.7816 mL | 1.9540 mL | |
| 25 mM | 0.0625 mL | 0.3126 mL | 0.6253 mL | 1.5632 mL | |
| 30 mM | 0.0521 mL | 0.2605 mL | 0.5211 mL | 1.3027 mL | |
| 40 mM | 0.0391 mL | 0.1954 mL | 0.3908 mL | 0.9770 mL | |
| 50 mM | 0.0313 mL | 0.1563 mL | 0.3126 mL | 0.7816 mL | |
| 60 mM | 0.0261 mL | 0.1303 mL | 0.2605 mL | 0.6513 mL | |
| 80 mM | 0.0195 mL | 0.0977 mL | 0.1954 mL | 0.4885 mL | |
| 100 mM | 0.0156 mL | 0.0782 mL | 0.1563 mL | 0.3908 mL |
Leritrelvir Related Classifications
HY-153121 Related Classifications
Powered by Bioz